 BristolMyers Squibb Co said the US Food and Drug Administration rejected its new drug application for its hepatitis C treatment in combination with other agents pending the submission of additional information requested by the regulator The pharmaceutical company said its regulatory filing had focused on the hepatitis C treatmentcalled daclatasvirin combination with another treatment called asunaprevir which the BristolMyers withdrew in October The company said that the FDA in a complete response letter requested
  